Skip to main content
Terug
Watch Compare

Actinium Pharmaceuticals, Inc.

Datakwaliteit: 100%
ATNM
NYSE Manufacturing Chemicals
€ 1,08
▼ € 0,06 (-5,26%)
Marktkapitalisatie: 34,67 M
Prijs
€ 1,11
Marktkapitalisatie
34,67 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -47,04% annually over 5 years
Negative free cash flow of -24,68 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 58,15%
Capital intensive — 115,56% of revenue goes to capex

Groei

Revenue Growth (5Y)
-47,04%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)11,11%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-206,65%
Onder sectorgemiddelde (-53,34%)
ROIC-55,06%
Net Margin-37652,22%
Op. Margin-40274,44%

Veiligheid

Debt / Equity
N/A
Current Ratio7,96
Interest CoverageN/A

Waardering

PE (TTM)
-1,02
Boven sectorgemiddelde (-1,47)
P/B Ratio2,52
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B 2,5 1,6
ROE % -206,7 -53,3
Net Margin % -37652,2 -41,5
Rev Growth 5Y % -47,0 1,8
D/E — 0,3

Koersdoel Analisten

5 analisten
Buy
Huidig
€ 1,08
+363.0%
Koersdoel
€ 5,00
€ 2,00
€ 5,00
€ 9,00
Vooruitzicht
Forward K/W -1,92
Forward WPA -€ 0,56
Omzet Sch. 12,93 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,56
-€ 0,85 – -€ 0,03
 12,93 M 3
FY2026 -€ 0,89
-€ 1,09 – -€ 0,66
 0,0 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,19 -€ 0,19 -1,8%
Q32025 -€ 0,32 -€ 0,16 +50,5%
Q22025 -€ 0,35 -€ 0,22 +37,6%
Q12025 -€ 0,28 -€ 0,51 -83,8%

ETFs Holding This Stock

BRSIX BRSIX
0,12% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 11,11% Revenue Growth (3Y) 5,41%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -47,04% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 90.000,0 Net Income (TTM) -33,89 M
ROE -206,65% ROA -56,87%
Gross Margin N/A Operating Margin -40274,44%
Net Margin -37652,22% Free Cash Flow (TTM) -24,68 M
ROIC -55,06% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,96
Interest Coverage N/A Asset Turnover 0,00
Working Capital 47,53 M Tangible Book Value 13,78 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,02 Forward P/E N/A
P/B Ratio 2,52 P/S Ratio 385,22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -71,20%
Market Cap 34,67 M Enterprise Value -18,72 M
Per Share
EPS (Diluted TTM) -1,09 Revenue / Share 0,00
FCF / Share -0,79 OCF / Share -0,78
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 115,56% FCF Conversion 72,84%
SBC-Adj. FCF -35,20 M Growth Momentum 58,15

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 90.000,0 81.000,0 81.000,0 1,03 M 1,14 M
Net Income -33,89 M -38,24 M -48,82 M -33,02 M -24,77 M
EPS (Diluted) -1,09 -1,27 -1,83 -1,37 —
Gross Profit — — — — —
Operating Income -36,25 M -42,12 M -51,92 M -34,10 M -24,96 M
EBITDA — — — — —
R&D Expenses 21,12 M 30,05 M 38,67 M 23,14 M 18,03 M
SG&A Expenses — — — — —
D&A 173.000,0 197.000,0 790.000,0 699.000,0 524.000,0
Interest Expense — — 3,10 M 1,09 M 190.000,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 51,78 M 76,90 M 81,45 M 114,19 M 80,39 M
Total Liabilities 43,94 M 44,14 M 45,07 M 47,71 M 6,84 M
Shareholders' Equity 7,83 M 32,76 M 36,38 M 66,48 M 73,55 M
Total Debt — — — — —
Cash & Equivalents 48,00 M 72,90 M 76,68 M 108,91 M 77,83 M
Current Assets 49,38 M 74,51 M 78,26 M 110,94 M 79,75 M
Current Liabilities 7,97 M 8,15 M 8,49 M 10,63 M 6,84 M